

Deborah Cromer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4921911/publications.pdf>

Version: 2024-02-01

54
papers

7,392
citations

257101

24
h-index

168136

53
g-index

68
all docs

68
docs citations

68
times ranked

11540
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. <i>Lancet Microbe</i> , The, 2022, 3, e52-e61.	3.4	436
2	Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e878-e879.	2.9	20
3	Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design. <i>Journal of Infectious Diseases</i> , 2022, 226, 236-245.	1.9	2
4	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 2022, 602, 654-656.	13.7	928
5	Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice. <i>Malaria Journal</i> , 2022, 21, 49.	0.8	2
6	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. <i>Nature Reviews Immunology</i> , 2022, 22, 387-397.	10.6	93
7	The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. <i>Immunity</i> , 2022, 55, 1316-1326.e4.	6.6	38
8	Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. <i>Nature Microbiology</i> , 2022, 7, 896-908.	5.9	32
9	Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. <i>Nature Communications</i> , 2021, 12, 1162.	5.8	316
10	Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	109
11	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. <i>Nature Reviews Immunology</i> , 2021, 21, 395-404.	10.6	223
12	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 1205-1211.	15.2	3,133
13	Decay of Fc-dependent antibody functions after mild to moderate COVID-19. <i>Cell Reports Medicine</i> , 2021, 2, 100296.	3.3	56
14	Influencing public health policy with data-informed mathematical models of infectious diseases: Recent developments and new challenges. <i>Epidemics</i> , 2020, 32, 100393.	1.5	31
15	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. <i>Nature Reviews Immunology</i> , 2020, 20, 727-738.	10.6	107
16	Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruption. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2020, 287, 20200354.	1.2	1
17	Plasmodium-specific antibodies block in vivo parasite growth without clearing infected red blood cells. <i>PLoS Pathogens</i> , 2019, 15, e1007599.	2.1	20
18	Functional cure of HIV: the scale of the challenge. <i>Nature Reviews Immunology</i> , 2019, 19, 45-54.	10.6	93

#	ARTICLE	IF	CITATIONS
19	Predictors of SIV recrudescence following antiretroviral treatment interruption. <i>ELife</i> , 2019, 8, .	2.8	18
20	Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency. <i>Journal of Virology</i> , 2018, 92, .	1.5	12
21	<i>In Silico</i> Investigation of the Decline in Clinical Efficacy of Artemisinin Combination Therapies Due to Increasing Artemisinin and Partner Drug Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	4
22	Quantification of host-mediated parasite clearance during blood-stage <i>Plasmodium</i> infection and anti-malarial drug treatment in mice. <i>International Journal for Parasitology</i> , 2018, 48, 903-913.	1.3	8
23	Within-host modeling of blood-stage malaria. <i>Immunological Reviews</i> , 2018, 285, 168-193.	2.8	26
24	Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?. <i>Journal of Virology</i> , 2017, 91, .	1.5	10
25	Characterising the effect of antimalarial drugs on the maturation and clearance of murine blood-stage <i>Plasmodium</i> parasites in vivo. <i>International Journal for Parasitology</i> , 2017, 47, 913-922.	1.3	19
26	A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage <i>Plasmodium falciparum</i> infection. <i>Journal of Theoretical Biology</i> , 2017, 430, 117-127.	0.8	9
27	Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. <i>Lancet Public Health</i> , The, 2017, 2, e367-e374.	4.7	72
28	Host-mediated impairment of parasite maturation during blood-stage <i>Plasmodium</i> infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7701-7706.	3.3	27
29	HIV-1 Mutation and Recombination Rates Are Different in Macrophages and T-cells. <i>Viruses</i> , 2016, 8, 118.	1.5	9
30	Estimating the in-vivo HIV template switching and recombination rate. <i>Aids</i> , 2016, 30, 185-192.	1.0	21
31	Defining the Effectiveness of Antimalarial Chemotherapy: Investigation of the Lag in Parasite Clearance Following Drug Administration. <i>Journal of Infectious Diseases</i> , 2016, 214, 753-761.	1.9	13
32	Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage <i>Plasmodium vivax</i> Infection and Its Potential as a Model to Evaluate Malaria Transmission. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005139.	1.3	39
33	Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days. <i>PLoS Pathogens</i> , 2016, 12, e1005740.	2.1	21
34	HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission. <i>PLoS Pathogens</i> , 2015, 11, e1005000.	2.1	92
35	Heme oxygenase-1 deficiency alters erythroblastic island formation, steady-state erythropoiesis and red blood cell lifespan in mice. <i>Haematologica</i> , 2015, 100, 601-610.	1.7	39
36	Quantifying Parameter and Structural Uncertainty of Dynamic Disease Transmission Models Using MCMC. <i>Medical Decision Making</i> , 2015, 35, 633-647.	1.2	13

#	ARTICLE	IF	CITATIONS
37	Modeling the Dynamics of Plasmodium vivax Infection and Hypnozoite Reactivation In Vivo. PLoS Neglected Tropical Diseases, 2015, 9, e0003595.	1.3	87
38	A general method to eliminate laboratory induced recombinants during massive, parallel sequencing of cDNA library. Virology Journal, 2015, 12, 55.	1.4	14
39	Epitope-Specific CD8+T Cell Kinetics Rather than Viral Variability Determine the Timing of Immune Escape in Simian Immunodeficiency Virus Infection. Journal of Immunology, 2015, 194, 4112-4121.	0.4	9
40	Reduced erythrocyte susceptibility and increased host clearance of young parasites slows Plasmodium growth in a murine model of severe malaria. Scientific Reports, 2015, 5, 9412.	1.6	15
41	Mice Deficient in the Putative Phospholipid Flippase ATP11C Exhibit Altered Erythrocyte Shape, Anemia, and Reduced Erythrocyte Life Span*. Journal of Biological Chemistry, 2014, 289, 19531-19537.	1.6	60
42	Effect of Mature Blood-Stage Plasmodium Parasite Sequestration on Pathogen Biomass in Mathematical and <i>In Vivo</i> Models of Malaria. Infection and Immunity, 2014, 82, 212-220.	1.0	26
43	The burden of influenza in England by age and clinical risk group: A statistical analysis to inform vaccine policy. Journal of Infection, 2014, 68, 363-371.	1.7	199
44	Fifteen to Twenty Percent of HIV Substitution Mutations Are Associated with Recombination. Journal of Virology, 2014, 88, 3837-3849.	1.5	31
45	Identifying Recombination Hot Spots in the HIV-1 Genome. Journal of Virology, 2014, 88, 2891-2902.	1.5	45
46	Where Have All the Parasites Gone? Modelling Early Malaria Parasite Sequestration Dynamics. PLoS ONE, 2013, 8, e55961.	1.1	9
47	Clinical Assessment of Anti-Viral CD8+ T Cell Immune Monitoring Using QuantiFERON-CMV [®] Assay to Identify High Risk Allogeneic Hematopoietic Stem Cell Transplant Patients with CMV Infection Complications. PLoS ONE, 2013, 8, e74744.	1.1	78
48	Anemia, Shortened Erythrocyte Lifespan and Stomatocytosis In a Flippase Mutant Mouse Strain. Blood, 2013, 122, 2183-2183.	0.6	0
49	A novel fluorescent-based assay reveals that thrombopoietin signaling and Bcl-XL influence, respectively, platelet and erythrocyte lifespans. Experimental Hematology, 2010, 38, 453-461.e1.	0.2	15
50	Limited CD4+ T cell proliferation leads to preservation of CD4+ T cell counts in SIV-infected sooty mangabeys. Proceedings of the Royal Society B: Biological Sciences, 2010, 277, 3773-3781.	1.2	24
51	How fast could HIV change gene frequencies in the human population?. Proceedings of the Royal Society B: Biological Sciences, 2010, 277, 1981-1989.	1.2	4
52	Low red cell production may protect against severe anemia during a malaria infection—Insights from modeling. Journal of Theoretical Biology, 2009, 257, 533-542.	0.8	28
53	Preferential invasion of reticulocytes during late-stage Plasmodium berghei infection accounts for reduced circulating reticulocyte levels. International Journal for Parasitology, 2006, 36, 1389-1397.	1.3	69
54	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature, 0, , .	13.7	104